Last reviewed · How we verify

Papillary thyroid carcinoma — Treatment Landscape & Competitive Intelligence

Papillary thyroid carcinoma (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Papillary thyroid carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lenvima LENVATINIB Eisai Kinase Inhibitor [EPC] Proto-oncogene tyrosine-protein kinase receptor Ret 2015-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Eisai · 1 drug in Papillary thyroid carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Papillary thyroid carcinoma:

Cite this brief

Drug Landscape (2026). Papillary thyroid carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/papillary-thyroid-carcinoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing